Original articleDiffuse neonatal hemangiomatosis: An evidence-based review of case reports in the literature
Section snippets
Methods
A literature search was performed using the National Library of Medicine PubMed database of the National Institutes of Health and Ovid MEDLINE database (1950-2009) using the search terms “neonatal hemangiomatosis,” “benign, hemangiomatosis,” and “diffuse hemangiomatosis,” along with the alternate spelling “haemangiomatosis” for all 3 search terms. All eligible articles were reviewed in detail and clinical characteristics were recorded. The authors identified key features distinguishing IH from
Results
Using the above search criteria, 180 articles were identified. Of the 180 articles, 95 were excluded for one or more of the following reasons: the article was not in English or was unavailable, case duplication, no case-specific information (ie, review articles without case reports), or a diagnosis other than multifocal vascular anomaly was made. The remaining 85 eligible articles were reviewed and a total of 110 cases were identified. Twenty-four cases were further excluded because they had
Discussion
Our study highlights the confusion in classifying and diagnosing multifocal vascular tumors of infancy and demonstrates that the term “diffuse neonatal hemangiomatosis” was used in the past to include IH, MLT, and likely other less well-characterized multifocal conditions.
The majority of cases reviewed were found to have IH, which is the most common vascular tumor of infancy (Fig 1). Infants with multiple cutaneous IH are recognized to have a higher risk of extracutaneous disease, the liver
References (19)
- et al.
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas
Hum Pathol
(2000) - et al.
Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas
J Pediatr
(1997) - et al.
Benign multiple diffuse neonatal hemangiomatosis after a pregnancy complicated by polyhydramnios and a placental chorioangioma
Eur J Obstet Gynecol Reprod Biol
(2003) - et al.
Diffuse neonatal hemangiomatosis
Pediatrics
(1970) - et al.
Neonatal dermal hematopoiesis associated with diffuse neonatal hemangiomatosis
Pediatr Dermatol
(1997) - et al.
Multiple diffuse hemangiomatosis: case report and review of the literature
Z Kinderheilkd
(1974) - et al.
Diffuse neonatal hemangiomatosis
Pediatr Dermatol
(1986) - et al.
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta
Arch Dermatol
(2001) - et al.
Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma
Plast Reconstr Surg
(1997)
Cited by (61)
Hemangioma Genetics and Associated Syndromes
2022, Dermatologic ClinicsCitation Excerpt :GI tract involvement is less common than hepatic IH, and clinically significant bleeding from these lesions is even rarer. Most cases of “hemangiomatosis” with GI bleeding are actually different types of vascular anomalies.12 Airway hemangiomas have also been reported in DNH.
Congenital Disseminated Pyogenic Granuloma: Characterization of an Aggressive Multisystemic Disorder
2020, Journal of PediatricsCitation Excerpt :In addition, extra-axial leptomeningeal and muscular lesions have been reported.26-28 Nevertheless, in an evidence-based review of 73 published cases reported to have diffuse neonatal hemangiomatosis, 43 had infantile hemangiomas, 17 had cutaneovisceral angiomatosis with thrombocytopenia, and 13 had multifocal vascular lesions, not otherwise specified.19 Of particular interest are reports of diffuse neonatal hemangiomatosis with multiple congenital vascular lesions involving the skin, brain, liver, spinal cord, muscles, lungs, pleura, intestine, and mesentery, described to have had poor response to corticosteroids.26-33
In utero embolization for placental chorioangioma and neonatal multifocal hemangiomatosis
2019, Journal of Gynecology Obstetrics and Human ReproductionMultifocal Infantile Hemangioma
2019, Journal of Pediatrics
Funding sources: None.
Disclosure: Dr Frieden is a consultant for Pierre-Fabre Dermatology. Drs Glick, Garzon, Mully, and Drolet have no conflicts of interest to declare.